10,563 results match your criteria Metastatic Carcinoma of the Skin

Comparative efficacy analysis identifies immune checkpoint blockade as a new survival benchmark in advanced cutaneous squamous cell carcinoma.

Eur J Cancer 2022 May 17;170:42-53. Epub 2022 May 17.

Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN) and Deutsches Zentrum Immuntherapie (DZI), Erlangen, Germany; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:

Background: Cutaneous squamous cell carcinoma is a common type of skin cancer that may progress to locally advanced or metastatic disease. Both disease stages are managed by a variety of treatment options, including immune checkpoint blockade (ICB), targeted therapy to epidermal growth factor, chemotherapy or treatment combinations. However, the comparative efficacy of such treatments is unclear. Read More

View Article and Full-Text PDF

[Diagnostics and treatment of secondary malignancies of the parotid gland-An overview].

HNO 2022 May 17. Epub 2022 May 17.

Medizinische Fakultät und Uniklinik Köln, Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Hals-Chirurgie, Universität zu Köln, Kerpener Str. 62, 50937, Köln, Deutschland.

Background: Secondary malignancies of the parotid gland frequently have a cutaneous origin and the incidence in central Europe is increasing.

Objective: The aim of this review article was to present the epidemiology, (differential) diagnostics and treatment of secondary malignancies of the parotid gland.

Material And Methods: A literature search of the current guidelines and evidence was carried out in the web-based databank PubMed. Read More

View Article and Full-Text PDF

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.

J Immunother Cancer 2022 May;10(5)

Drug Development Department, Gustave Roussy Institute, Villejuif, France.

Background: This phase 1b study (NCT02323191) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of colony-stimulating factor-1 receptor-blocking monoclonal antibody (mAb) emactuzumab in combination with the programmed cell death-1 ligand (PD-L1)-blocking mAb atezolizumab in patients with advanced solid tumors naïve or experienced for immune checkpoint blockers (ICBs).

Methods: Emactuzumab (500-1350 mg flat) and atezolizumab (1200 mg flat) were administered intravenously every 3 weeks. Dose escalation of emactuzumab was conducted using the 3+3 design up to the maximum tolerated dose (MTD) or optimal biological dose (OBD). Read More

View Article and Full-Text PDF

Advanced basal cell carcinoma: What dermatologists need to know about treatment.

J Am Acad Dermatol 2022 06;86(6S):S14-S24

St. Luke's University Health Network, Easton.

The treatment of advanced basal cell carcinoma (BCC) often requires therapies beyond local surgical excision or radiation due to the invasiveness of the tumor. Historically, cytotoxic chemotherapy was used to treat advanced BCC, but with limited data, no standard regimens were established. The discovery of cyclopamine, a natural inhibitor in the Hedgehog pathway, led to the development of the 2 currently approved Hedgehog inhibitors, vismodegib and sonidegib. Read More

View Article and Full-Text PDF

Rare malignant adnexal tumour of the skin involving distal phalanx of right thumb with co-existing primary lung cancer in a 72-year-old patient: A case report.

Int J Surg Case Rep 2022 May 10;95:107174. Epub 2022 May 10.

Department of General Surgery, Mata Chanan Devi Hospital, New Delhi, India.

Introduction And Importance: Malignant adnexal tumours of the skin are a group of rare malignancies. These tumours can further differentiate into eccrine, apocrine, sebaceous, sweat duct, or ceruminous glands within the skin or follicular cells. Sebaceous carcinoma, a malignant adnexal tumour of the skin, is a rare and malignant tumour of the sebaceous glands. Read More

View Article and Full-Text PDF

Deep Convolutional Neural Support Vector Machines for the Classification of Basal Cell Carcinoma Hyperspectral Signatures.

J Clin Med 2022 Apr 21;11(9). Epub 2022 Apr 21.

Department of Mining Technology, Topography and Structures, University of León, Av. Astorga s/n, 24401 Ponferrada, Spain.

Non-melanoma skin cancer, and basal cell carcinoma in particular, is one of the most common types of cancer. Although this type of malignancy has lower metastatic rates than other types of skin cancer, its locally destructive nature and the advantages of its timely treatment make early detection vital. The combination of multispectral imaging and artificial intelligence has arisen as a powerful tool for the detection and classification of skin cancer in a non-invasive manner. Read More

View Article and Full-Text PDF

Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma.

J Immunother Cancer 2022 May;10(5)

Division of Hematology and Oncology, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA.

Background: Basal cell carcinoma (BCC) is the most common malignancy worldwide, yet the management of patients with advanced or metastatic disease is challenging, with limited treatment options. Recently, programmed death receptor 1 (PD-1) inhibition has demonstrated activity in BCC after prior Hedgehog inhibitor treatment.

Methods: We conducted a multicenter, retrospective analysis of BCC patients treated with PD-1 inhibitor therapy. Read More

View Article and Full-Text PDF

Chronic lymphoedema: a nidus for squamous cell carcinoma.

BMJ Case Rep 2022 May 10;15(5). Epub 2022 May 10.

Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, Delhi, India.

Lymphoedema is a chronic debilitating condition characterised by diffuse swelling caused by lymphatic obstruction. The secondary form of lymphoedema is more common than the primary form. Untreated filariasis remains an important cause of lymphoedema in developing countries. Read More

View Article and Full-Text PDF

Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation.

Transplant Cell Ther 2022 May 6. Epub 2022 May 6.

Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA. Electronic address:

Background: Total body irradiation in combination with melphalan for multiple myeloma (MM), was shown to be prohibitively toxic. To ameliorate toxicity, total marrow irradiation (TMI), was given as the sole ablative modality during the second cycle of tandem autologous stem cell transplant (TASCT) for MM patients on a phase I-II trial.

Study Design: Patients with MM in response or with stable disease and ≤ 18 months from diagnosis received melphalan (MEL) 200 mg/m and ASCT (Cycle 1), and, after recovery, TMI and ASCT (Cycle 2) followed by maintenance with an IMiD and dexamethasone for up to 12 months. Read More

View Article and Full-Text PDF

Bullous pemphigoid associated with squamous cell lung carcinoma showing remarkable response to carboplatin-based chemotherapy:  a case report.

J Med Case Rep 2022 May 5;16(1):184. Epub 2022 May 5.

Northwest Cancer Centre, Tamworth Hospital, Dean Street, Tamworth, NSW, 2340, Australia.

Background: Bullous pemphigoid is an uncommon dermatologic manifestation seen in squamous cell lung cancer, and evidence guiding optimal treatment, especially in the elderly population, is limited. We report herein a case of squamous cell lung cancer diagnosed after being investigated for refractory bullous pemphigoid showing marked response to carboplatin-based chemotherapy. This is the first case report that shows carboplatin can be used as an effective alternative in treatment of malignancy-associated bullous pemphigoid. Read More

View Article and Full-Text PDF

Basal cell carcinomas acquire secondary mutations to overcome dormancy and progress from microscopic to macroscopic disease.

Cell Rep 2022 05;39(5):110779

Department of Dermatology, Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address:

Basal cell carcinomas (BCCs) frequently possess immense mutational burdens; however, the functional significance of most of these mutations remains unclear. Here, we report that loss of Ptch1, the most common mutation that activates upstream Hedgehog (Hh) signaling, initiates the formation of nascent BCC-like tumors that eventually enter into a dormant state. However, rare tumors that overcome dormancy acquire the ability to hyperactivate downstream Hh signaling through a variety of mechanisms, including amplification of Gli1/2 and upregulation of Mycn. Read More

View Article and Full-Text PDF

Immunotherapy for recurrent or metastatic vulvar carcinoma: A case report and review of current guidelines.

Gynecol Oncol Rep 2022 Jun 19;41:100982. Epub 2022 Apr 19.

Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

There are limited treatment options for patients with advanced vulvar cancer. However, several immune checkpoint inhibitors (ICIs) are FDA-approved or NCCN-Compendia-listed for qualified patients with advanced disease. In this case report, we present a patient with metastatic vulvar squamous cell carcinoma who was treated with pembrolizumab in the setting of disease progression following prior treatment with radiation and chemotherapy. Read More

View Article and Full-Text PDF

Feasibility, Tolerance, and Quality of Life for Hypofractionation Versus Conventional Fractionation for Post-mastectomy Radiotherapy in Indian Patients.

Cureus 2022 Mar 25;14(3):e23497. Epub 2022 Mar 25.

Clinical Oncology, Indian Institute of Head and Neck Oncology, Indore, IND.

Introduction: The international standard for post-operative radiotherapy for breast cancer delivers hypofractionated radiotherapy. However, many centers in India still follow the longer conventional schedule probably because of paucity of large prospective trials in Indian patients on the same and apprehension regarding tolerance of high dose per fraction in the said population. We aimed to test the feasibility of hypofractionation in our setting and compared the toxicities and the quality of life in patients receiving conventional and hypofractionated radiotherapy. Read More

View Article and Full-Text PDF

Hematuria in breast cancer: don't forget bladder metastases!

Pathologica 2022 Apr;114(2):170-173

University of Salerno, Department of Medicine and Surgery, Baronissi (SA), Italy.

The bladder is a rare site for breast cancer metastases, and only occasional reports are present in the literature. Most cases coexist with synchronous metastases elsewhere, but isolated cases of a single metastatic localization in the urinary bladder have been reported. The most common symptoms of a metastatic localization of breast cancer to the urinary bladder are hematuria and voiding dysfunction. Read More

View Article and Full-Text PDF

Cancer Progression Gene Expression Profiling Identifies the Urokinase Plasminogen Activator Receptor as a Biomarker of Metastasis in Cutaneous Squamous Cell Carcinoma.

Front Oncol 2022 11;12:835929. Epub 2022 Apr 11.

Illawarra Health and Medical Research Institute (IHMRI), Wollongong, NSW, Australia.

Cutaneous squamous cell carcinoma (cSCC) of the head and neck region is the second most prevalent skin cancer, with metastases to regional lymph nodes occurring in 2%-5% of cases. To further our understanding of the molecular events characterizing cSCC invasion and metastasis, we conducted targeted cancer progression gene expression and pathway analysis in non-metastasizing (PRI-) and metastasizing primary (PRI+) cSCC tumors of the head and neck region, cognate lymph node metastases (MET), and matched sun-exposed skin (SES). The highest differentially expressed genes in metastatic (MET and PRI+) versus non-metastatic tumors (PRI-) and SES included , , , , , , , and various inflammatory cytokine genes. Read More

View Article and Full-Text PDF

Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial.

JAMA Dermatol 2022 Apr 27. Epub 2022 Apr 27.

Department of Dermatology, Maastricht University Medical Center, Maastricht, the Netherlands.

Importance: Treatment of actinic keratosis (AK) aims to prevent cutaneous squamous cell carcinoma (cSCC). However, whether AK can progress into invasive cSCC is a matter of debate, and little is known about the effect of treatment on preventing cSCC.

Objectives: To evaluate the risk of invasive cSCC and factors that may contribute to increased risk in patients with multiple AKs. Read More

View Article and Full-Text PDF

Metastatic Neuroendocrine Tumors to Parotid Gland: Where Do They Come From?

Int J Surg Pathol 2022 Apr 24:10668969221095267. Epub 2022 Apr 24.

Department of Pathology, 2468Rush University Medical Center, Chicago, Illinois, USA.

. Metastasis to parotid gland occurs mostly from skin cancers of the head and neck region. Metastatic neuroendocrine tumors to the parotid gland are rare and not well studied so far. Read More

View Article and Full-Text PDF

Poorly Differentiated Metastatic Carcinoma of Possible Eccrine Sweat Gland Origin.

Am Surg 2022 Apr 24:31348221091944. Epub 2022 Apr 24.

Division Chief, Surgical Oncology, Department of Surgery, School of Medicine, 21693University of Mississippi Medical Center, Jackson, MS, USA.

Sweat gland carcinomas are a rare group of cancer, representing less than .01% of all diagnosed skin malignancies. We report the case of a 32-year-old male who presented with a fungating lesion on the posterolateral side of his left knee. Read More

View Article and Full-Text PDF

Squamous Cell Carcinoma in Patients with Inherited Epidermolysis Bullosa: Review of Current Literature.

Cells 2022 Apr 17;11(8). Epub 2022 Apr 17.

Section of Pathology, Department of Emergency and Organ Transplantation (DETO), University of Bari "Aldo Moro", 70124 Bari, Italy.

Epidermolysis bullosa (EB) is a group of rare congenital diseases caused by mutations in structural proteins of the dermal/epidermal junction that are characterized by extreme epithelial fragility, which determines the formation of bullae and erosions either spontaneously or after local mechanical traumas. In EB patients, skin fragility leads to many possible complications and comorbidities. One of the most feared complications is the development of cutaneous squamous cell carcinomas (SCCs) that particularly in the dystrophic recessive EB subtype can be extremely aggressive and often metastatic. Read More

View Article and Full-Text PDF

Head and Neck Cancer Susceptibility and Metabolism in Fanconi Anemia.

Cancers (Basel) 2022 Apr 18;14(8). Epub 2022 Apr 18.

Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.

Fanconi anemia (FA) is a rare inherited, generally autosomal recessive syndrome, but it displays X-linked or dominant negative inheritance for certain genes. FA is characterized by a deficiency in DNA damage repair that results in bone marrow failure, and in an increased risk for various epithelial tumors, most commonly squamous cell carcinomas of the head and neck (HNSCC) and of the esophagus, anogenital tract and skin. Individuals with FA exhibit increased human papilloma virus (HPV) prevalence. Read More

View Article and Full-Text PDF

Renal cell carcinoma with early skin metastasis and partial response on tyrosine kinase inhibitor: A case report.

Int J Surg Case Rep 2022 Apr 5;94:107020. Epub 2022 Apr 5.

Department of Surgery, Oncology Division, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

Introduction And Importance: Renal cell carcinoma (RCC) skin metastasis is a rare disease. However, there are no data on the effect of a Tyrosine Kinase Inhibitor (TKI) on its treatment.

Case Presentation: A 54-year-old male patient with renal cell carcinoma developed subcutaneous metastasis three months after radical nephrectomy and there was no discoloration or pain. Read More

View Article and Full-Text PDF

Metastatic basal cell carcinoma of buccal mucosa: a report of a rare case.

World J Surg Oncol 2022 Apr 21;20(1):127. Epub 2022 Apr 21.

Department of Oral Diagnosis and Medicine, Hokkaido University Graduate School of Dental Medicine, Sapporo, Japan.

Background: Basal cell carcinoma (BCC) is the most common cancer worldwide. Most of BCCs can be detected in the early stages and are generally well controlled with local resection. Despite the high incidence of BCC, metastasis is rarely observed. Read More

View Article and Full-Text PDF

EGFR Targeting TKI-Related Skin Toxicities in a Patient with Darker Skin: A Case Report.

Curr Oncol 2022 Apr 5;29(4):2509-2515. Epub 2022 Apr 5.

Department of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, Sunnybrook Health Science Centre, Toronto, ON M4N 3M5, Canada.

Epidermal growth factor receptor (EGFR) targeting tyrosine kinase inhibitors (TKIs) can result in significant skin toxicities that may impact patients' quality of life. While these skin reactions are well documented in patients with lighter skin, there is a paucity of literature and images to guide clinicians in their assessment in patients with darker skin tones. Given that dermatological reactions in patients with darker skin are not well represented, this can result in the undertreatment or mistreatment of these otherwise common toxicities. Read More

View Article and Full-Text PDF

Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis.

Curr Oncol 2022 Mar 23;29(4):2193-2198. Epub 2022 Mar 23.

Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway.

Basal cell carcinoma (BCC) is the most common cancer in Caucasians. It is slow growing and rarely metastasizes. If left untreated over time, invasive growth can occur. Read More

View Article and Full-Text PDF

Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.

Thyroid 2022 May 17. Epub 2022 May 17.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Sorafenib and lenvatinib have been widely adopted to treat radioactive iodine (RAI)-refractory differentiated thyroid carcinoma (DTC). However, limited data exist regarding a direct comparison of these tyrosine kinase inhibitors (TKIs). We aimed to evaluate the clinical efficacy and safety of two TKIs as first-line therapy in patients with distant metastatic or locally advanced, progressive, RAI-refractory DTC in real-world practice. Read More

View Article and Full-Text PDF

Pilot trial of topical MTS‑01 application to reduce dermatitis in patients receiving chemoradiotherapy for stage I‑III carcinoma of the anal canal.

Int J Oncol 2022 Jun 19;60(6). Epub 2022 Apr 19.

HIV and AIDS Malignancy Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.

The purpose of the present trial was to determine the feasibility of the daily topical application of the piperidine nitroxide, MTS‑01, combined with chemoradiotherapy in the treatment of patients with anal carcinoma. The secondary study endpoints were the description of the effects of this agent on skin toxicity and rectal‑associated lymphoid tissue. The participants received radiotherapy concurrent with mitomycin‑C and 5‑fluorouracil for carcinoma of the anal canal. Read More

View Article and Full-Text PDF

A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.

Invest New Drugs 2022 Apr 18. Epub 2022 Apr 18.

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Background: Tarloxotinib, a hypoxia-activated prodrug of an irreversible pan-ErbB tyrosine kinase inhibitor, represents a novel therapeutic which exploits the tumor-specific hypoxic environment as a mechanism for tumor-specific targeting. This study evaluated the safety and activity of tarloxotinib in recurrent or metastatic (R/M) cutaneous (CSCC) or head and neck squamous cell carcinoma (HNSCC).

Methods: This was a phase II two-stage multi-centre study for patients with R/M HNSCC or CSCC. Read More

View Article and Full-Text PDF

Primary cutaneous adenoid cystic carcinoma - An onerous task for clinicians and pathologists.

Indian J Pathol Microbiol 2022 Apr-Jun;65(2):459-461

Department of Pathoogy, Navodaya Medical College, Raichur, Karnataka, India.

Adenoid cystic carcinoma (ACC) is an uncommon malignant neoplasm usually confined to the salivary glands, lungs, and breasts. Primary cutaneous adenoid cystic carcinoma (PCACC) is an extremely rare entity with solitary cases reported at sites away from the scalp and chest. Hence, one must follow the multidisciplinary approach to exclude any primary ACC elsewhere in the body. Read More

View Article and Full-Text PDF

Metastatic renal cell carcinoma presenting as subcutaneous nodule.

Radiol Case Rep 2022 Jun 8;17(6):1973-1976. Epub 2022 Apr 8.

Departments of Radiology, Louisiana State University, Shreveport, LA, 71103, University of Texas Medical Branch, Galveston, TX 77555, USA.

Renal cell carcinoma is frequently undiagnosed until it reaches an advanced metastatic stage. Renal cell cancers are also seen as incidental findings on imaging, and rarely can present as physical examination findings. We report a rare case where metastatic renal cell carcinoma presented as a solitary 2 cm subcutaneous chest wall nodule in an otherwise asymptomatic male patient. Read More

View Article and Full-Text PDF

Treatment of in-transit Merkel cell carcinoma by isolated limb infusion with cytotoxic drugs.

J Surg Case Rep 2022 Apr 12;2022(4):rjac172. Epub 2022 Apr 12.

Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.

Merkel cell carcinoma of the skin is a rare but aggressive malignancy, which predominantly affects older adults with fair skin. Isolated limb infusion (ILI) using melphalan and actinomycin D was first developed as a minimally invasive treatment option to treat unresectable metastatic melanoma confined to the limb. We report on a 62-year-old male with in-transit metastases (ITMs) treated with ILI to highlight the ongoing role this treatment has when all other therapies have been exhausted. Read More

View Article and Full-Text PDF